Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
-
Fuchs, Charles S. (Harvard Medical School)
;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Tomášek, Jiří (Masaryk University (Czech Republic)) ;
Chau, Ian (Royal Marsden Hospital (Regne Unit)) ;
Melichar, Bohuslav (Univerzity Palackeho a Fakultni nemocnice (Czech Republic)) ;
Safran, Howard (Brown University Oncology Research Group (USA)) ;
Tehfe, Mustapha A. (Centre Hospitalier de Montréal (Canada)) ;
Filip, Dumitru (Spitalul Judetean de Urgenta (Romania)) ;
Topuzov, Eldar (Northwest State Medical University na II Mechnikov) ;
Schlittler, Luis (Hospital da Cida de Passo Fundo (Brasil)) ;
Udrea, Anghel Adrian (Medisprof SRL (Romania)) ;
Campbell, William (Hospital Herrera Llerandi (Guatemala)) ;
Brincat, Stephen (Sir Anthony Mamo Oncology Centre (Malta)) ;
Emig, Michael (Lilly Deutschland GmbH (Germany)) ;
Melemed, Symantha A. (Lilly Corporate Center (USA)) ;
Hozak, Rebecca R. (Lilly Corporate Center (USA)) ;
Ferry, David (Lilly Corporate Center (USA)) ;
Caldwell, C. William (Lilly Corporate Center (USA)) ;
Ajani, Jaffer A. (The University of Texas MD Anderson Cancer Center (USA)) ;
Universitat Autònoma de Barcelona
guest ::
Subscribe to this discussion. You will then receive all new comments by email.
